Searchable abstracts of presentations at key conferences in endocrinology

ea0056p1029 | Thyroid (non-cancer) | ECE2018

Single session treatment of benign thyroid nodules with radiofrecuency ablation: results at 6 months in 17 patients

Familiar Cristina , Merino Salome , Ganado Tomas , Jimenez Ines , Sanabria Concepcion

Introduction: Radiofrecuency ablation (RFA) represents an alternative to surgery for benign thyroid nodules with pressure symptoms or evident progressive growth.Objetives: To analyze in our center the efficacy and safety at 6 montns of a single session treatment of RFA performed in predominantly solid thyroid nodules.Patients and methods: 17 patients with citologically benign thyroid nodules with pressure symptoms (dysphonia, dyspn...

ea0056p1128 | Thyroid cancer | ECE2018

Highly sensitive Thyroglobulin assay in monitoring patients treated for differentiated thyoid cancer in 26 consecutive patients

Jimenez Ines , Familiar Cristina , Azcutia Anne , Ramos Elvira , Barrio Elvira

Introduction: Guidelines suggest that serum basal (nonstimulated) thyroblobulin (bTg) with sensitive assays (Functional Sensitivity-FS- below 0.1 or 0.2 ng/ml) could substitute the measurement of serum Tg levels after TSH stimulation during the follow-up of patients with differentiated thyroid cancer (DTC) when basal results fall below the FS.Objective: A sensitive assay for Tg was incorporate in our center (Chemiluminiscent Tg Access; Beckam Coulter; Br...

ea0045p8 | Bone | BSPED2016

Denosumab therapy for hypercalcaemia of malignancy in a young child

Saravanamuthu Abiramy , Katugampola Harshini , Collard Grace , Matei Cristina , Peters Catherine

Introduction: Hypercalcaemia secondary to malignancy is rare in childhood. Bisphosphonates have previously been shown to be effective in managing such cases in adults, however caution must be exercised in patients with renal failure or respiratory compromise. Denosumab, a RANKL monoclonal antibody is a very potent inhibitor of osteoclasts and can induce hypocalcaemia. It is not excreted by the kidney. Limited trials in adults have shown denosumab to have greater efficacy compa...

ea0073pep13.4 | Presented ePosters 13: Pituitary and Neuroendocrinology | ECE2021

Long term management in aggressive thyrotropinoma

Stanca Oana , Stancu Cristina , Dumitrascu Anda , Badiu Corin

IntroductionThyrotropinoma is a rare pituitary tumor ( <2% of pituitary adenomas) arising from PIT1-lineage cells, which expresses and secrete TSH. In most cases, the etiology is unknown but rare cases have been described to arise in context of MEN 1 syndrome. Diagnosis is often delayed by confusion with primary hyperthyroidism, which determine the tumor to be already large and invasive at the time of diagnosis. GH and prolactin cosecretion is an increas...

ea0075a16 | Adrenal gland | EYES2021

An alternative preoperative management of pheochromocytoma

Mourinho Bala Nadia , Guerra Silvia , Maria Aragues Jose , Valadas Cristina

Background: A pheochromocytoma is a rare neuroendocrine tumor, originating from adrenomedullary chromaffin cells. The pre-surgical management of pheochromocytoma is classically performed with alpha-blockers. However, in some cases other pharmacological approaches can be considered.Objective: The aim of the study is to describe the clinical course of patients with pheochromocytoma prepared for surgery with calcium channel blockers (CCB).<p class="abst...

ea0092ps1-03-02 | Miscellaneous 1 | ETA2023

Safety and efficacy of prophylactic treatment for hyperthyroidism induced by iodinated contrast media in a high-risk population

Manso Jacopo , Piva Ilaria , Censi Simona , Clausi Cristina , Mian Caterina

Introduction: The use of iodinated contrast media (ICM) can lead to thyrotoxicosis, especially in patients with risk factors, such as Graves’ disease, multinodular goiter, older age, and iodine deficiency. Although hyperthyroidism may have clinically relevant effects, whether high-risk patients should receive prophylactic treatment before they are administered ICM is still debated.Aim of the study: We aimed to demonstrate the safety and efficacy of ...

ea0099p444 | Calcium and Bone | ECE2024

Hyperostosis frontalis interna – a case of Morgagni–Stewart–Morel syndrome

Radulescu Vlad , Stanescu Anastasia , Stancu Cristina , Badiu Corin

Introduction: Morgagni–Stewart–Morel syndrome is defined as the absolute presence of hyperostosis frontalis interna, associated with metabolic, endocrine, and neuropsychiatric disorders. There are very few cases reported in the literature and some experts do not even recognize it but the exact etiology of the syndrome remains unclear; some theories relate to estrogen dysfunction, obesity and leptin dysfunction, and genetic alterations....

ea0099p313 | Pituitary and Neuroendocrinology | ECE2024

TGFBR3L gene expression and relevance for the gonadotroph non-functioning pituitary neuroendocrine tumours

Wessel Maren , Petter Berg Jens , Bollerslev Jens , Cristina Olarescu Nicoleta

Objective: Transforming growth factor beta receptor 3 like (TGFBR3L) has been recently described as a pituitary-specific membrane protein detected in a proportion of the gonadotroph cells in non-neoplastic and tumour tissue (1). Furthermore, mouse studies have indicated that TGFBR3L is an inhibin B co-receptor that regulates FSH levels (2). We hypothesized that TGFBR3L expression in gonadotroph non-functioning pituitary neuroendocrine tumours (NF-PitNETs) is related to clinica...

ea0099ep1173 | Calcium and Bone | ECE2024

Secondary hyperparathyroidism after total en bloc gastrectomy due to Non-Hodgkin’s lymphoma

Gratiela Bratu , Radulescu Vlad , Stancu Cristina , Badiu Corin

Introduction: Primary hyperparathyroidism is a condition in which one or more parathyroid glands have a pathological secretion of parathyroid hormone due to their abnormal function. Secondary hyperparathyroidism has normal parathyroid glands, but an abnormal secretion of PTH because of an underlying condition that influence their activity. It is important to differentiate between primary and secondary hyperparathyroidism because of the different treatment.<p class="abstext...

ea0099ep667 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Osteocalcin: relation to glucose metabolism in young women with obesity

Carolina Piterschi , Stela Vudu , Cristina Rizov , Vudu Lorina

Introduction: Osteocalcin is a bone-specific hormone also involved in regulation of glucose and fat mass metabolism. It regulates energy expenditure by acting on adipocytes and pancreatic islet cells. The aim of the present study was to examine the relation between serum osteocalcin and glucose metabolism in young women with obesity. Material and methods: A total of 66 healthy women were included in the analysis. Data on body mass index (BMI), waist circ...